LONDON, Aug. 01, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017
Time: 3:05 PM EDT
Location: New York, NY
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / James White | ||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||
| ICR, Inc. (US Media and Investor enquiries) | ||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



